theheart.org: Acute Coronary Syndromes (ACS) news and education

Acute Coronary Syndromes

Oct 30, 2009 10:23 EDT

PLATO, CURRENT-OASIS 7, and further analyses of PPIs and thienopyridines; read Dr Prasad's review of recent data presented at ESC; and watch presentations by Drs Mehran, O'Donoghue, Storey, and Wiviott.

Acute Coronary Syndromes

Antiplatelet Therapy: Autumn Poll

Oct 26, 2009 08:59 EDT

PLATO, CURRENT-OASIS 7, COGENT, recent meetings have seen some blockbuster presentations in the area of antiplatelet/antithrombotic therapy. What is your response to these data? Answer our 4 short polling questions and learn your peers' responses.

Acute Coronary Syndromes

Antiplatelet Therapy in ACS: The Latest Dialogues

Oct 15, 2009 16:09 EDT

PLATO, the ESC late-breaking trial, compared a novel direct-acting reversible P2Y12 antagonist with clopidogrel in ACS patients undergoing PCI. Dr. Keith Fox leads a discussion with the PI, Dr. Lars Wallentin, and Dr. Deepak Bhatt.

Interventional/Surgery

Dual Antiplatelet Therapy: Dueling Options in Real-World Practice

1 COMMENT - Sep 30, 2009 13:31 EDT

With the recent approval of a third-generation thienopyridine, choice of agent can be added to the list of considerations in the management of ACS patients, as well as the appropriate timing and dosing of thienopyridine. Using some case vignettes, Dr. King leads a discussion with Drs. Bhatt and Steg on their clinical decision-making.

Acute Coronary Syndromes

In Brief: Optimal Use of Dual Antiplatelet Therapy...

Sep 15, 2009 15:44 EDT

Antiplatelet therapy is key for the prevention of secondary events in ACS patients. Dr. Ardissino introduces a series of brief presentations by Drs. Angiolillo, Fernánadez-Avilés, Montalescot, and Neumann on the optimal use of antiplatelets in ACS patients undergoing PCI, including those with diabetes and those at high bleeding risk.

Acute Coronary Syndromes

Antiplatelet Therapy in PCI: Addressing Unmet Needs

Aug 28, 2009 11:29 EDT

How will the prasugrel approval and the upcoming PLATO and CURRENT-OASIS 7 trials affect antiplatelet options for ACS patients undergoing PCI? Read a summary of the latest data, with expert input from Drs. Ardissino and Montalescot.

Acute Coronary Syndromes

Managing Bleeding Complications in PCI

Aug 12, 2009 13:40 EDT

A patient suffers a STEMI after exploratory laparotomy for suspected gastrinoma; their surgeon insists that no anticoagulation be given. How would you treat? Dr. Rao presents such a complicated case to Dr. Montalescot.

Acute Coronary Syndromes

Antiplatelet Therapy: A Brazilian Expert's Take

1 COMMENT - Jul 14, 2009 12:00 EDT

From SOLACI 2009 in Rio de Janeiro. Dr. Mahmud hears how Dr. Feres interprets the data on antiplatelet/antithrombin strategies for his practice in Brazil.

Acute Coronary Syndromes

Antiplatelet Therapy: The Latin American Perspective

Jul 1, 2009 13:57 EDT

HORIZONS-AMI has influenced US practice; after TRITON-TIMI 38, the potential role of prasugrel is a hot topic. How has Latin America responded to these data? Recorded at SOLACI 2009, Dr. Mahmud has an information exchange on contemporary antiplatelet management with two of Argentina's leading interventionalists, Drs. Grinfeld and Londero.

Acute Coronary Syndromes

Antiplatelet Therapy: Summer Poll

8 COMMENTS - Jun 22, 2009 00:07 EDT

Early-ACS, HORIZONS-AMI, On-TIME 2... How do you use GP IIb/IIIa inhibitors in contemporary practice? Given the continued uncertainty regarding the optimal duration of dual antiplatelet therapy, what do you do for AF patients on warfarin who need stents? Answer our 3 short polling questions and learn your peers' responses.

Acute Coronary Syndromes

IIb or Not IIb: The Role of GP IIb/IIIa Inhibitors in ACS

Jun 15, 2009 13:47 EDT

After EARLY-ACS and HORIZONS-AMI, the utility of routine GP IIb/IIIa inhibitors in contemporary management of ACS patients has been challenged. Studies of prehospital and pre-angiography administration have yielded mixed results, largely reflecting different trial designs. Dr. Gershlick aims to clarify matters with Drs. Hamm and Mehran.

Acute Coronary Syndromes

Antiplatelet Therapy in an ACS Patient With Diabetes

May 5, 2009 00:00 EDT

Patients with diabetes have more reactive platelets and are also more likely to have a diminished response to antiplatelet therapy. Dr. Angiolillo presents Dr. Storey with a case illustrating issues in the management of antiplatelet therapy in an ACS patient with diabetes.

Acute Coronary Syndromes

Antiplatelet Pharmacogenetics: Can We Tailor Therapy?

2 COMMENTS - Apr 23, 2009 00:00 EDT

Carriers of certain CYP genetic variants have lower levels of clopidogrel's active metabolite and experience higher rates of MACE. Could genotyping help optimize antiplatelet therapy? Common PPIs also inhibit CYP enzymes and may impair clopidogrel efficacy. Dr. Topol discusses recent data on these topics with Drs. Montalescot, Sabatine, and Simon.

Acute Coronary Syndromes

Antiplatelet Therapy: Spring Poll

Mar 23, 2009 00:00 EDT

Are you concerned about the effects of genetics and proton pump inhibitors on antiplatelet efficacy? How will you incorporate novel agents? Answer 4 short polling questions and learn what your colleagues do.

Acute Coronary Syndromes

Year in Review: STEMI Adjunctive Pharmacologic Management

Mar 17, 2009 00:00 EDT

The adjunctive pharmacologic regimen for the management of patients with STEMI is influenced by local practice and preferences in addition to emerging clinical study data. Join Drs. Fox, Hamm, and Mehran as they discuss the implications of some of last year's top trials including HORIZONS-AMI, TRITON-TIMI 38, On-TIME 2, FINESSE and BRAVE. Then hear Dr. Ohman's take on facilitated PCI.

Acute Coronary Syndromes

Antiplatelet Options for ACS: The Changing Landscape

Feb 12, 2009 09:00 EST

On February 3, 2009, the FDA's Cardiovascular and Renal Drugs Advisory Committee unanimously voted to recommend approval of the novel thienopyridine prasugrel for use in ACS patients undergoing PCI. Drs. Nissen, Ohman, Kandzari, Topol, and Steg each give their take on the likely implications for clinical practice and remaining issues of concern in the optimal management of patients with ACS.

Acute Coronary Syndromes

The Future of Platelet Inhibition in Acute Coronary Syndromes

Dec 29, 2008 09:39 EST

Data on new antiplatelet therapies that may help optimize antiplatelet therapy and decrease morbidity and mortality in patients with acute coronary syndromes (ACS) is emerging. Join Drs Steg, Montalescot, Morrow, and Windecker as they highlight these data and treatment strategies to effectively manage ACS patients.

Acute Coronary Syndromes

Highlights From Preventing Ischemic Events Following PCI: Addressing the Issues and Controversies

Dec 19, 2008 09:00 EST

Antiplatelet agents, such as aspirin, the thienopyridines, and the glycoprotein IIb/IIIa inhibitors, have proven to be effective in reducing the incidence of adverse events that are associated with plaque rupture in patients following PCI. Join our experts as they discuss the current issues and controversies related to the overall management of these patients and the use of antiplatelet therapy.

Acute Coronary Syndromes

Focus on Cardiovascular Disease and Diabetes

1 COMMENT - Dec 11, 2008 10:38 EST

The International Diabetes Federation estimates that diabetes accounts for approximately 6% of total global mortality. Some 50% of diabetes-associated deaths can be directly attributed to cardiovascular disease. Join our expert panel, Drs Bhatt, Morrow, Van de Werf, and Wiviott, as the review the new data on early detection and interventions for these patients

Acute Coronary Syndromes

The Fellowship Series: Managing Stent Thrombosis

2 COMMENTS - Dec 9, 2008 09:30 EST

Stent thrombosis remains a serious complication of stent implantation despite the use of antiplatelet therapy. Join Drs Ohman and Jolicoeur for a case presentation of a challenging stent thrombosis case.

Acute Coronary Syndromes

Managing Oral Antiplatelet Therapy

1 COMMENT - Dec 1, 2008 18:59 EST

Data has shown that oral antiplatelet therapy management practices vary widely. Answer 3 short polling questions in the Antiplatelet Therapies section and see what your colleagues do.

Acute Coronary Syndromes

Drug-Eluting Stents and Noncardiac Surgery

9 COMMENTS - Nov 24, 2008 10:30 EST

The management of patients with drug-eluting stents who are undergoing noncardiac surgery can be challenging. Join Dr Mahmud and panelists Drs Eagle and Kandzari as they review a difficult case.

Acute Coronary Syndromes

Acute and Long-term Therapy in Patients Undergoing PCI

1 COMMENT - Nov 19, 2008 09:00 EST

New data has shown that anticoagulant/antiplatet therapy reduce the incidence of bleeding and improve bleeding and improve outcomes in patients undergoing PCI. Join Dr Ohman and panelists Drs Mehran, Bates, and Montalescot as they discuss the treatment options and as they discuss strategies to implement these new data.

Acute Coronary Syndromes

Updates to the STEMI Guidelines

7 COMMENTS - Aug 18, 2008 15:25 EDT

Both the US and the European Guidelines for the Management of STEMI have recently been revised to reflect new data specific to the management and treatment of STEMI patients. Join Dr E Magnus Ohman and panelists Drs Robert Harrington, Robert Storey and Jean-Pierre Bassand as they discuss the differences between the US and the European STEMI Guidelines as well as the optimal management goals for patients with STEMI.

Acute Coronary Syndromes

Highlights from oral antiplatelet therapy for acute and chronic management of ischaemic heart disease

2 COMMENTS - Jul 18, 2008 14:09 EDT

With several new oral antiplatelet agents looming large on the horizon, don't miss this unique opportunity to hear the experts share new clinical data and analysis!

Acute Coronary Syndromes

Balancing risk and benefit

Jan 15, 2008 14:01 EST

Take a second to answer a series of new polling questions in the Antiplatelet Therapies section. Let us know your experience with balancing risk and benefit in light of all current treatment options.

	Yes, at greater than or equal to 100 mg/day
	Yes, at less than 100 mg/day
	No